CURRENT LOCATION:
HOME》Technology transfer》Chemical technology transfer》New transfer》Dabigatran etexilate
Dabigatran etexilate

     

    Project NameDabigatran etexilate 

    Registration Classification3.1

    Formulations and specifications 150mg capsules 

    IndicationsDabigatran etexilate is a novel synthetic direct thrombin inhibitor , a prodrug of dabigatran , the case of non-peptidic inhibitors of thrombin . There are risks applicable to patients with non- valvular atrial fibrillation to reduce stroke and systemic embolism . Stroke, atrial fibrillation (AF) to prevent initiation .

    Original Research CompanyGerman company Boehringer Ingelheim research and development, in 2008, Germany and the United Kingdom. 

    Progress Pharmaceutical Research in progress

     

Links:

地址:北京市丰台区造甲街南里5号4A楼2层
电话:010-63716441 63717341 传真:010-63728443
COPYRIGHT (C) 2014 Beijing Mega Pharmaceutical Science and Technology Co.,ltd. ALL RIGHTS RESERVED
版权所有 北京满格医药科技有限公司 京ICP备12000952号